Pub-2021

Articles

Title
Single-Agent Ibrutinib for Rituximab-Refractory Waldenstrom Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate Trial
How to Sequence Therapies in Waldenström Macroglobulinemia
A prognostic index predicting survival in transformed Waldenström macroglobulinemia
Predictors of response and survival in a large cohort of 319 Waldenström macroglobulinemia patients treated with ibrutinib monotherapy
Plasmablastic lymphoma transformation in a patient with Waldenstrom macroglobulinemia treated with ibrutinib
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenstrom macroglobulinemia
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom’s Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTK-Cys481 ibrutinib resistance
Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome
Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88-L265P in Waldenström Macroglobulinemia
Epigenetic targeting of Waldenstrom macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition
Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia
Reducing treatment toxicity in Waldenström macroglobulinemia
Partial response or better at six months is prognostic of superior progression-free survival in Waldenstrom macroglobulinaemia patients treated with ibrutinib
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia
CXCR4 in Waldenström’s Macroglobulinema: chances and challenges
Clinical application of genomics in Waldenström macroglobulinemia
Cell-free DNA analysis for detection of MYD88-L265P and CXCR4-S338X mutations in Waldenström macroglobulinemia
Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenstr€om macroglobulinaemia